BackRhythm Pharmaceuticals Overview
Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Target Price

See Rhythm Pharmaceuticals's analyst price targets ($150) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$115.25

Average Target Price

$148.1428.5% upside

7 analysts in the last 4 months

High: $160 | Low: $133

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05Canaccord Genuity$15433.6% upsideOpen
2026-08-05National Bank$16038.8% upsideOpen
2026-07-07RBC Capital$14122.3% upsideOpen
2026-06-16Canaccord GenuityWhitney Ijem$15131% upsideOpen
2026-06-15Stifel NicolausPaul Matteis$13315.4% upsideOpen
2026-06-15Wells Fargo$15534.5% upsideOpen
2026-05-07Canaccord Genuity$14324.1% upsideOpen
2026-03-12Telsey Advisory$14324.1% upsideOpen
2026-03-12Wells Fargo$14324.1% upsideOpen
2026-03-03JefferiesDennis Ding$1258.5% upsideOpen
2026-02-26Stifel NicolausPaul Matteis$13113.7% upsideOpen
2026-02-18RBC CapitalLisa Walter$14525.8% upsideOpen
2026-01-20H.C. Wainwright$1258.5% upsideOpen
2026-01-20Wells FargoDerek Archila$14525.8% upsideOpen
2025-12-22H.C. WainwrightRaghuram Selvaraju$1236.7% upsideOpen
2025-12-17GuggenheimSeamus Fernandez$14021.5% upsideOpen
2025-12-12Goldman Sachs$15736.2% upsideOpen
2025-12-12Canaccord GenuityWhitney Ijem$14122.3% upsideOpen
2025-12-11Morgan Stanley$15030.2% upsideOpen
2025-10-17Goldman SachsCorinne Johnson$13920.6% upsideOpen
2025-10-16Morgan Stanley$12911.9% upsideOpen
2025-09-29H.C. WainwrightRaghuram Selvaraju$1104.6% downsideOpen
2025-09-25JMP SecuritiesJonathan Wolleben$14223.2% upsideOpen
2025-08-05Morgan Stanley$1095.4% downsideOpen
2025-07-10OppenheimerLeland Gershell$1104.6% downsideOpen
2025-07-10Goldman SachsCorinne Johnson$9715.8% downsideOpen
2025-07-09Morgan StanleyMichael Ulz$9517.6% downsideOpen
2025-03-05Stifel Nicolaus$7832.3% downsideOpen
2025-03-03H.C. Wainwright$7039.3% downsideOpen
2025-01-01JefferiesDennis Ding$8030.6% downsideOpen
2024-12-05Goldman SachsCorinne Jenkins$6642.7% downsideOpen
2024-11-06NeedhamAlan Carr$6444.5% downsideOpen
2024-11-06Goldman SachsCorinne Jenkins$5948.8% downsideOpen
2024-09-18H.C. WainwrightRaghuram Selvaraju$6444.5% downsideOpen
2024-09-17JMP SecuritiesJonathan Wolleben$6444.5% downsideOpen
2024-07-25NeedhamAlan Carr$5552.3% downsideOpen
2022-11-10Goldman Sachs$3569.6% downsideOpen
2022-08-07Goldman SachsCorinne Jenkins$2875.7% downsideOpen
2022-07-12Goldman SachsCorinne Jenkins$694.8% downsideOpen
2022-06-17Needham$2578.3% downsideOpen
2022-06-17Stifel NicolausDae Gon Ha$2578.3% downsideOpen

Rhythm Pharmaceuticals (RYTM) FAQ

Rhythm Pharmaceuticals posts a target price of $150. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $150 for RYTM means covering analysts, on average, see the stock 28.5% upside of $115.25 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for RYTM's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Rhythm Pharmaceuticals's other metric pages and overview cover the third.

Judging Rhythm Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $150 here, then scan peer and history charts to see if the gap is persistent.